- Published at
- by manilatimes.net
positive
positive
News for Xeris Pharmaceuticals, Inc. (XERS)
- Published at
- by manilatimes.net
positivepositive- Published at
- by seekingalpha.com
neutralneutralXeris Pharmaceuticals Q4 2024 Earnings Preview (NASDAQ:XERS)
Discover what to expect as Xeris Pharmaceuticals (XERS) reports Q4 earnings on March 6th.- Published at
- by gurufocus.com
positivepositiveThe American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
PR NewswireCHICAGO and ARLINGTON, Va., Jan. 21, 2025 Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lower- Published at
- by investing.com
mixedmixedEarnings call: Xeris Biopharma sees 26% revenue surge in Q2 2024 By Investing.com
Earnings call: Xeris Biopharma sees 26% revenue surge in Q2 2024- Published at
- by seekingalpha.com
neutralneutralXeris Pharmaceuticals Q2 2024 Earnings Preview (NASDAQ:XERS)
Xeris Pharmaceuticals (XERS) Q2 earnings results to be announced on August 8th.- Published at
- by seekingalpha.com
neutralneutralXeris Pharmaceuticals Q1 2024 Earnings Preview (NASDAQ:XERS)
Xeris Pharmaceuticals is set to announce Q1 earnings on May 9th.- Published at
- by insidermonkey.com
positivepositiveXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript
Operator: Hello everyone and welcome to the Xeris fourth quarter and full year 2023 financial results conference call and webcast. My name is Emily and I’ll be coordinating your call today.- Published at
- by investing.com
mixedmixedEarnings call: Xeris Biopharma reports robust growth and strategic refinancing By Investing.com
Earnings call: Xeris Biopharma reports robust growth and strategic refinancing- Published at
- by seekingalpha.com
neutralneutralXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84M (NASDAQ:XERS)
Xeris Pharmaceuticals reports Q4 2023 financial results, beating revenue expectations.- Published at
- by seekingalpha.com
neutralneutralXeris Pharmaceuticals Q4 2023 Earnings Preview (NASDAQ:XERS)
Xeris Pharmaceuticals is set to announce Q4 earnings results, with expectations of a -$0.09 EPS and $43.55M revenue, based on upward revisions.- Published at
- by insidermonkey.com
mixedmixedXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2023 Earnings Call Transcript
Operator: Hello, everyone and welcome to the Xeris Biopharma Third Quarter 2023 Financial Results Call. My name is Bruno. I'll be operating your call today.- Published at
- by globenewswire.com
neutralneutralAutoinjectors Market Size to Surpass USD 233.69 Billion by 2030, exhibiting a CAGR of 11.2%
According to the report by Fortune Business Insights, the global autoinjectors market size is projected to reach USD 233.69 billion by 2030, at a CAGR of...- Published at
- by marketscreener.com
positivepositiveXeris Ships One Millionth Gvoke® Unit
Updated guidelines recognize the benefits of ready-to-use glucagon Protecting all people with diabetes at risk of severe hypoglycemia remains the goal ...- Published at
- by markets.businessinsider.com
positivepositiveFDA Grants Orphan-drug Exclusivity For Xeris' Recorlev For Endogenous Cushing's Syndrome Treatment
(RTTNews) - Xeris Biopharma Holdings Inc. (XERS) said Monday that the U.S. Food and Drug Administration granted its subsidiary Xeris Pharmaceutica...- Published at
- by prnewswire.com
mixedmixedGlobal Bio-Pharma Market is Expected to reach USD 703.28 Billion by 2027 at 12.5% CAGR, Says Brandessence Market Research
/PRNewswire/ -- Global Bio-Pharma Market is valued at USD 274.10 Billion in 2020 and is expected to reach USD 703.28 Billion by 2027 with a CAGR of 12.5% over...- Published at
- by etfdailynews.com
mixedmixedResearch Analysts’ Upgrades for May 19th (AAVMY, AAWW, AIT, AMOT, AMRN, AMZN, ATO, BCH, BCS, BECN)
Read Research Analysts’ Upgrades for May 19th (AAVMY, AAWW, AIT, AMOT, AMRN, AMZN, ATO, BCH, BCS, BECN) at ETF Daily NewsZLDPFZEALYUEIYYUEIFXGNWSFSVSSYWVS.CNVSVRTSVRSSFVODUPSTTUFNSWMAYSWMAFSTEM.LSSMXYSSMXFSRNESMARSBG-UNSBGPRLBPFSIOWLTOSHOROPGNOBSVN.MXOBSVOBSN.SWNICXFNEWTJMPLYJMPLFJMAT.LJEF.MXJEFITCBITAUCORP.SNHSBC.BAHSBC-PAHSBCHSBA.LHSB.PAHBCYFHBCN.MXHBC1.DEH1SB34.SACSCOCOX.PABECNAMZNAAVMY6869N.MX6869.T0RCQ.L0L85.L0KRR.L0GO4.L0A8L.L0551.HK0005.HKXERSXWPPUEPSUEUBSN.MXUBSGEE.SWUBSGE.SWUBSG34.SAUBSG.SWUBSTACSYBXSGE.DESCGLYSCGLFRPMROPRMBSRCELPSALLPSA.MXPSA-PQPSA-PPPSAOSMTORKLYORKLFORK.OLOLKOCUPNTCTNKTXNDRAWNDRAMMYTMKTWLPTXLNNGYLNNGFLANCKNYJYKNYJFKC4.DEJPMMLJPMISSDYISFFFHEGSGI34.SAGS.MXGS.BAGSGOS.DEGLEN.MXGLE.PAFOJCYFOJCFFBIOEPREACTMXBCSBCHAVHHLAVH.AXATOAMOTAITACND-UNACND2331N.MX2331.HK0A8U.L0A8E.LDBN.MXDBK.PRDBK.MIDBK.DEDB- Published at
- by etfdailynews.com
mixedmixedXeris Biopharma (NASDAQ:XERS) Upgraded at Zacks Investment Research
Read Xeris Biopharma (NASDAQ:XERS) Upgraded at Zacks Investment Research at ETF Daily News- Published at
- by news.google.com
neutralneutralPDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development
PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development - read this article along with other careers information, tips and advice on BioSpace- Published at
- by globenewswire.com
neutralneutralPDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development
Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)...